Tumor-treating electric fields show early promise in NSCLC — boosting both Novocure and its Chinese biotech partner

Amber Tong

More than a decade after the FDA first approved electric fields as a treatment for glioblastoma, Novocure said it’s seen a promising signal that they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tumor-treating electric fields show early promise in NSCLC — boosting both Novocure and its Chinese biotech partner

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial

Startup working on oral antibodies shares early ulcerative colitis data

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

How AI can address ongoing challenges in the life sciences industry

Tu­mor-treat­ing elec­tric fields show ear­ly promise in NSCLC — boost­ing both Novo­cure and its Chi­nese biotech part­ner

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Tumor-treating electric fields show early promise in NSCLC — boosting both Novocure and its Chinese biotech partner